Open Access Research Article

Prognostic Value of Serum Uric Acid Levels to the Cardiovascular Events in Hypertensives

MV Papavasileiou1, G Moustakas1, A Karamanou1*, SPatsianis1, D Aravantinos1 and A Pittaras2

1Sismanoglion GH Cardiology, Antihypertensive clinic Athens, Greece

2Mediton Cardiology Diagnostic Center, Athens, Greece

Corresponding Author

Received Date:January 04, 2021;  Published Date:February 15, 2021


Aim: The aim of the study was to investigate the association of serum uric acid (SUA) levels with the major cardiovascular events (MACE) in hypertensive patients.

Methods and Materials: This is a prospective analysis including 652 hypertensive patients (52,6% female) of mean age at the entry: 57,2±13,1 years, mean office systolic/diastolic blood pressure (S/DBPo): 152,3±19,1/94,4±11,83 mmHg, mean office heart rate (HRo): 76,0±12 beats/min, treated or newly diagnosed untreated. The median follow-up period was 9 years. SUA were measured at the entry of the study. Major cardiovascular events (MACE) (myocardial infarction, unstable angina, transient ischemic attack or stroke, peripheral vascular intervention, heart failure events, cardiovascular death) were registered. We estimated the prognostic value of SUA to the MACE. Cox proportional hazard model was employed to determine the prognostic value of uric acid.

Result:The median follow-up period was 9 years. There were 264 (40,5%) MACE at the end of the study. Cox regression statistical analysis revealed that SUA was a strong predictor of MACE (HR: 1,14, 95%CI: 1,06 – 1,2 p-value=0,000)

Conclusion: SUA levels have statistically significant prognostic value to MACE in hypertensive patients.

Signup for Newsletter
Scroll to Top